IMA901: Completed Phase III enrollment

immatics completed enrollment of about 345 patients in the open-label, international Phase III IMPRINT trial comparing intradermal IMA901 plus Sutent sunitinib vs. Sutent alone. Pfizer Inc. (NYSE:PF...